SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (6911)5/28/2003 1:31:26 AM
From: Icebrg  Read Replies (1) of 10280
 
>>They could abandon Claritin, let Clarinex go OTC and finally keep Soltara as their prescription drug

I'd be very surprised indeed if this were to happen. SGP isn't going to give up the 20+% of the antihistamine market held by Clarinex in exchange for a not-yet-approved drug. Also, the FTC would need quite a bit of convincing, which would cause unacceptable delay. >>

You are right. I thought that they could wait with the disposal until they actually had the approval. There should be no logic reason for FTC to demand that they give up a drug they cannot sell yet.

But considering how things actually are done - latest demonstrated in the Pfizer/Pharmacia merger with the two ED-drugs Pfizer had to give up - it appears that it doesn't matter if a drug is under development or not.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News